Previous studies showed that combinations of radiation [9] or targeted agents, everolimus [10] and altiratinib [11], with CDK4/6 inhibitors have synergistic effects against GBM cells and tumor growth in vitro and in vivo. The gene discussed is CDK4; the disease is glioblastoma.